6 completed, 4 terminated, 2 not yet recruiting, 1 recruiting. 13 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 6, Terminated 4, Not yet recruiting 2, Recruiting 1 |
| Phase 2 | 4 | Completed 2, Terminated 2 |
Follow Peritoneal Carcinoma: new trials by email Literature Review of Peritoneal Carcinoma trials Research Report on Peritoneal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer (Arginaid®) Oral Arginine, (R-Gene® 10) IV Arginine, Pembrolizumab - Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers | Phase 1 | Not yet recruiting | Rebecca Arend | 24 | 2026-09-01 | 2026-10-15 |
| SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer SCT-001 CAR-T cells - Ovarian Cancer, Fallopian Tube Carcinoma | Phase 1 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 24 | 2025-06-01 | 2025-02-26 |
| Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors vvDD-hIL-2-RG-1 - Gastric Neoplasms, Esophageal Cancer | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 18 | 2025-05-06 | 2025-06-03 |
| NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NM32-2668 - Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 1 | Terminated | Numab Therapeutics AG | 11 | 2024-05-01 | 2025-07-23 |
| Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer Oxaliplatin, mFOLFIRI - Colorectal Cancer, Appendiceal Cancer | Phase 1 | Terminated | University of Utah | 1 | 2021-03-22 | 2021-09-27 |
| A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors NM21-1480 - Advanced Solid Tumor, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Numab Therapeutics AG | 52 | 2020-08-19 | 2025-05-23 |
| Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC Radspherin - Peritoneal Carcinoma, Colorectal Carcinoma | Phase 1 / Phase 2 | Completed | Oncoinvent Solutions AS | 47 | 2020-05-27 | 2025-08-28 |
| A Trial Evaluating TG4050 in Ovarian Carcinoma. TG4050 - Ovarian Carcinoma, Fallopian Tube Cancer | Phase 1 | Completed | Transgene | 64 | 2019-12-09 | 2025-11-14 |
| Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer ribociclib, Paclitaxel, Carboplatin - Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Completed | Ronald Buckanovich | 35 | 2017-06-10 | 2022-09-07 |
| CAR T Cells in Mesothelin Expressing Cancers huCART-meso cells - Lung Adenocarcinoma, Ovarian Cancer | Phase 1 | Completed | University of Pennsylvania | 65 | 2017-04-06 | 2025-04-29 |
| Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer carboplatin - FIGO Stage IIC-IV Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 1 | Completed | University of California, Irvine | 30 | 2014-07-01 | 2020-01-31 |
| Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer trientine dihydrochloride, pegylated liposomal doxorubicin, carboplatin - Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma | Phase 1 / Phase 2 | Completed | National Cheng-Kung University Hospital | 18 | 2012-09-01 | 2020-11-10 |
| Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma Pazopanib, Doxil - Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | SCRI Development Innovations, LLC | 22 | 2010-01-01 | 2021-10-28 |
Fallopian Tube Neoplasms (10) · Ovarian Neoplasms (7) · Colorectal Neoplasms (3) · Adenocarcinoma of Lung (2) · Mesothelioma, Malignant (2) · Triple Negative Breast Neoplasms (2) · Appendiceal Neoplasms (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Leiomyosarcoma (1)
Neoplasms by Site (13) · Neoplasms (12) · Adnexal Diseases (10) · Fallopian Tube Diseases (10) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Genital Diseases (10) · Genital Diseases, Female (10) · Genital Neoplasms, Female (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Gonadal Disorders (8) · Ovarian Diseases (8)
Carboplatin (3) · Paclitaxel (2) · liposomal doxorubicin (2) · Arginine (1) · Bevacizumab (1) · Cyclophosphamide (1) · Dimethoate (1) · Oxaliplatin (1) · Platinum (1) · Trientine (1) · pazopanib (1) · pembrolizumab (1) · ribociclib (1)
Numab Therapeutics AG (2) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · National Cheng-Kung University Hospital (1) · Oncoinvent Solutions AS (1) · Rebecca Arend (1) · Ronald Buckanovich (1) · SCRI Development Innovations, LLC (1) · Shanghai Gynecologic Oncology Group (1) · Transgene (1) · University of California, Irvine (1) · University of Pennsylvania (1) · University of Utah (1)
United States (10) · China (1) · France (1) · Norway (1) · Spain (1) · Sweden (1) · Taiwan (1)
Janos L Tanyi, MD, PhD (1) · Krishnansu Tewari, MD (1) · Lan G Coffman, M.D. (1) · Laura Lambert, MD (1) · Patrick Wagner, MD (1) · Rebecca C Arend, MD (1) · T.Michael Numnum, MD (1)
PMID 31179244, PMID 35972817, PMID 36936230, PMID 41424175
2018 (1)